ABSTRACT Introduction Venous thromboembolism (VTE) is labeled as an adverse effect of the adeno‐vector‐based vaccines AstraZeneca and Johnson & Johnson. We aimed to study whether there was an increase in general practitioner (GP) consultations for VTE after COVID‐19 vaccination. Methods An exposure‐anchored self‐controlled cohort study was performed among COVID‐19 vaccinated persons aged ≥ 12 years who were registered in the PHARMO Data Network and Nivel Primary Care Database in the Netherlands. The focal window was set at 28 days after each COVID‐19 vaccination and the referent window at all time outside the focal window. Adjusted incidence rate ratios (aIRR), adjusting for SARS‐CoV‐2 infection, were calculated using Poisson regression. Results In total, 2 133 853 persons were included. The highest increase in GP consultations for VTE was observed after Johnson & Johnson vaccination (aIRR: 3.14, 95% CI: 1.50–6.57), and a slight increase after Pfizer/BioNTech dose 1 (aIRR: 1.24, 95% CI: 1.09–1.40). Risk groups were 12–60 year‐olds with increased GP consultations for VTE after Johnson & Johnson (aIRR: 2.30, 95% CI: 1.44–3.69) and Pfizer/BioNTech (aIRR: 1.29, 95% CI: 1.11–1.50), and in specific groups of males aged 12–60 years. Also, females using hormone‐containing contraceptives or hormone replacement therapy (HRT) showed increased GP consultations for VTE after AstraZeneca (aIRR: 2.87, 95% CI: 1.13–7.33) and Pfizer/BioNTech (aIRR: 1.48, 95% CI: 1.10–2.01). Conclusion Increased GP consultations for VTE were observed after both vector and mRNA vaccination, in particular among males, 12–60 year olds, and females using hormone‐containing contraceptives or HRT.
Jajou et al. (Thu,) studied this question.